Skip to main content

Liletta Disease Interactions

There are 12 disease interactions with Liletta (levonorgestrel).

Major

Contraceptives (applies to Liletta) abnormal genital bleeding

Major Potential Hazard, Moderate plausibility. Applicable conditions: Abnormal Uterine Bleeding

The use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding. Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.

References

  1. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical
  2. (2006) "Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals
  3. (2016) "Product Information. Liletta (levonorgestrel)." Actavis Pharma, Inc.
Major

Estrogens/progestogens (applies to Liletta) hepatic neoplasms

Major Potential Hazard, High plausibility. Applicable conditions: Hepatic Tumor

The use of oral contraceptives is contraindicated in patients with liver tumors. An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively. Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver. Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.

References

  1. Tao LC (1991) "Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma." Cancer, 68, p. 341-7
  2. (1991) "Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives." Int J Cancer, 49, p. 182-5
  3. Conter RL, Longmire WP Jr (1988) "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg, 207, p. 115-9
  4. Aldinger K, Ben-Menachem Y, Whalen G (1977) "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med, 137, p. 357-9
  5. Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S (1989) "Oral contraceptive use and liver cancer." Am J Epidemiol, 130, p. 878-82
  6. Mooney MJ, Nyreen MR, Hall RA, Carter PL (1993) "Hepatic adenoma presenting as a right lower quadrant mass." Am Surg, 59, p. 229-31
  7. Gyorffy EJ, Bredfeldt JE, Black WC (1989) "Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use." Ann Intern Med, 110, p. 489-90
  8. Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C (1993) "Female hormone utilisation and risk of hepatocellular carcinoma." Br J Cancer, 67, p. 635-7
  9. Mathieu D, Zafrani ES, Anglade MC, Dhumeaux D (1989) "Association of focal nodular hyperplasia and hepatic hemangioma." Gastroenterology, 97, p. 154-7
  10. Le Bail B, Jouhanole H, Deugnier Y, Salame G, Pellegrin JL, Saric J, Balabaud C, Bioulac-Sage P (1992) "Liver adenomatosis with granulomas in two patients on long-term oral contraceptives." Am J Surg Pathol, 16, p. 982-7
  11. (1992) "Oral contraceptives and neoplasia. WHO Scientific Group." World Health Organ Tech Rep Ser, 817, p. 1-46
  12. Mishell DR (1989) "Contraception." N Engl J Med, 320, p. 777-85
  13. (2001) "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories
  14. (2001) "Product Information. Climara (estradiol)." Berlex Laboratories
  15. (2001) "Product Information. Estrace (estradiol)." Warner Chilcott Laboratories
  16. (2001) "Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals
  17. (2001) "Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals
  18. "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
  19. (2001) "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical
  20. "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
  21. (2001) "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories
  22. (2001) "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical
  23. (2001) "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories
  24. "Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical
  25. (2001) "Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical
  26. "Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical
  27. (2001) "Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn
  28. "Product Information. Estinyl (ethinyl estradiol)." Schering Corporation
  29. (2001) "Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc
  30. (2001) "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories
  31. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical
  32. (2001) "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories
  33. (2006) "Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals
  34. (2021) "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma
View all 34 references
Major

Progestogens (applies to Liletta) breast malignancy

Major Potential Hazard, High plausibility. Applicable conditions: Breast Cancer

The use of progestogens is considered by manufacturers to be contraindicated in patients with existing or suspected malignancy of the breast. Some supportive data are available for medroxyprogesterone. Specifically, medroxyprogesterone treatment may be associated with breast cancer, primarily when the drug is administered intramuscularly. A pooled analysis of two case-control studies, one from the World Health Organization and the other from New Zealand, revealed a small overall relative risk of breast cancer in women who have ever used intramuscular medroxyprogesterone acetate. The relative risk was higher in the subgroup of women who had initiated therapy within the previous 5 years. Thus, an increased risk (approximately 2-fold) is associated with intramuscular medroxyprogesterone use in the first 5 years. A more recent U.S. study also found a statistically significant increase in breast cancer risk among recent users (defined as last use within the past five years) who used depo-medroxyprogesterone acetate for 12 months or longer.

References

  1. Liang AP, Levenson AG, Layde PM, Shelton JD, Hatcher RA, Potts M, Michelson MJ (1983) "Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections." JAMA, 249, p. 2909-12
  2. (1984) "Breast cancer, cervical cancer, and depot medroxyprogesterone acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives" Lancet, 2, p. 1207-8
  3. (1991) "Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives" Lancet, 338, p. 833-8
  4. Jordan A (1994) "Toxicology of depot medroxyprogesterone acetate." Contraception, 49, p. 189-201
  5. Chilvers C (1994) "Breast cancer and depot-medroxyprogesterone acetate - a review." Contraception, 49, p. 211-22
  6. (2001) "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn
  7. (2001) "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn
  8. Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB (1995) "Depot medroxyprogesterone acetate and breast cancer." JAMA, 273, p. 799-807
  9. (2001) "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories
  10. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical
  11. (2001) "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories
  12. (2001) "Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC
  13. (2006) "Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals
View all 13 references
Major

Progestogens (applies to Liletta) liver disease

Major Potential Hazard, High plausibility.

The use of progestogens, in general, is contraindicated in patients with impaired hepatic function or liver disease. There are little or no data concerning the pharmacokinetic disposition of the different progestogens in patients with hepatic disease. However, most hormones, including progestational hormones, are known to be extensively metabolized by the liver. Medroxyprogesterone should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur.

References

  1. Utaaker E, Lundgren S, Kvinnsland S, Aakvaag A (1988) "Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer." J Steroid Biochem, 31, p. 437-41
  2. Castegnaro E, Sala G (1971) "Pharmacokinetics and metabolism of medroxyprogesterone acetate. Influence of the route of administration and of its physical state." Steroidologia, 2, p. 13-26
  3. Riippa P, Kauppila A, Sundstrom H, Vihko R (1984) "Hepatic impairment during simultaneous administration of medroxyprogesterone acetate and tamoxifen in the treatment of endometrial and ovarian carcinoma." Anticancer Res, 4, p. 109-12
  4. Meyer WJ, 3d Wiener I, Emory LE, Cole CM, Isenberg N, Fagan CJ, Thompson JC (1992) "Cholelithiasis associated with medroxyprogesterone acetate therapy in men." Res Commun Chem Pathol Pharmacol, 75, p. 69-84
  5. Hendeles SM, Galand N, Schwers J (1972) "Metabolism of orally administered D-norgestrel in women." Acta Endocrinol (Copenh), 71, p. 557-68
  6. (2001) "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn
  7. (2001) "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn
  8. (2001) "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories
  9. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical
  10. (2001) "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories
  11. (2001) "Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC
  12. (2006) "Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals
View all 12 references
Moderate

Estrogens/progestogens (applies to Liletta) depression

Moderate Potential Hazard, Moderate plausibility.

The use of oral contraceptives has been associated with an increased incidence of depression. It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression. Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely. The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.

References

  1. (2001) "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn
  2. (2001) "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn
  3. (2001) "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories
  4. (2001) "Product Information. Climara (estradiol)." Berlex Laboratories
  5. (2001) "Product Information. Estrace (estradiol)." Warner Chilcott Laboratories
  6. (2001) "Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals
  7. (2001) "Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals
  8. "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
  9. (2001) "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical
  10. "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
  11. (2001) "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories
  12. (2001) "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical
  13. (2001) "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories
  14. "Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical
  15. (2001) "Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical
  16. "Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical
  17. (2001) "Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn
  18. "Product Information. Estinyl (ethinyl estradiol)." Schering Corporation
  19. (2001) "Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc
  20. (2001) "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories
  21. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical
  22. (2001) "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories
  23. (2006) "Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals
  24. (2021) "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma
View all 24 references
Moderate

Estrogens/progestogens (applies to Liletta) fluid retention

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Migraine, Asthma, Seizures, Congestive Heart Failure, Hypertension

Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods. Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid. In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.

References

  1. Leiman G (1972) "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure." Am J Obstet Gynecol, 114, p. 97-102
  2. (2001) "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn
  3. (2001) "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn
  4. (2001) "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories
  5. (2001) "Product Information. Climara (estradiol)." Berlex Laboratories
  6. (2001) "Product Information. Estrace (estradiol)." Warner Chilcott Laboratories
  7. (2001) "Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals
  8. (2001) "Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals
  9. "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
  10. (2001) "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical
  11. "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
  12. (2001) "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories
  13. (2001) "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical
  14. (2001) "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories
  15. "Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical
  16. (2001) "Product Information. Emcyt (estramustine)." Pharmacia and Upjohn
  17. (2001) "Product Information. Megace (megestrol)." Bristol-Myers Squibb
  18. (2001) "Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical
  19. "Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical
  20. (2001) "Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn
  21. "Product Information. Estinyl (ethinyl estradiol)." Schering Corporation
  22. (2001) "Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc
  23. (2001) "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories
  24. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical
  25. (2001) "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories
  26. (2001) "Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC
  27. (2006) "Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals
View all 27 references
Moderate

Estrogens/progestogens (applies to Liletta) glucose intolerance

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose. However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent. Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.

References

  1. Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE (1989) "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception, 39, p. 619-32
  2. Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D (1986) "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet, 24, p. 291-6
  3. Who Task Force on Long-acting Agents for Fertility Regulation (1986) "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ, 64, p. 587-94
  4. Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE (1994) "Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus." JAMA, 271, p. 1099-102
  5. Hannaford PC, Kay CR (1989) "Oral contraceptives and diabetes mellitus." BMJ, 299, p. 1315-6
  6. Stubblefield PG (1989) "Choosing the best oral contraceptive." Clin Obstet Gynecol, 32, p. 316-28
  7. Spellacy WN, Ellingson AB, Tsibris JC (1989) "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril, 51, p. 71-4
  8. Steinberg WM (1989) "Oral contraception: risks and benefits." Adv Contracept, 5, p. 219-28
  9. Derman R (1989) "Oral contraceptives: a reassessment." Obstet Gynecol Surv, 44, p. 662-8
  10. Belchetz PE (1994) "Hormonal treatment of postmenopausal women." N Engl J Med, 330, p. 1062-71
  11. Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV (1993) "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med, 38, p. 207-14
  12. Kaunitz AM (1994) "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol, 170, p. 1543-9
  13. "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
  14. "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
  15. (2001) "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical
  16. "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
  17. (2001) "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories
  18. (2001) "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical
  19. (2001) "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories
  20. "Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical
  21. (2001) "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories
  22. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical
  23. (2001) "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories
  24. (2021) "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma
View all 24 references
Moderate

Estrogens/progestogens (applies to Liletta) retinal thrombosis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Visual Defect/Disturbance

Estrogens and progestogens may cause retinal thrombosis. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted. Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.

References

  1. "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
  2. "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
  3. (2001) "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical
  4. "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
  5. (2001) "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories
  6. (2001) "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical
  7. (2001) "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories
  8. "Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical
  9. (2001) "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories
  10. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical
  11. (2001) "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories
  12. (2001) "Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC
  13. (2021) "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma
View all 13 references
Moderate

Estrogens/progestogens (applies to Liletta) thyroid function tests

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Thyroid Disease

When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests. Changes have mostly been reported with the use of combination oral contraceptives. Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay. Free T3 resin uptake may be decreased. On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.

References

  1. (2001) "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn
  2. (2001) "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn
  3. (2001) "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories
  4. (2001) "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn
  5. (2001) "Product Information. Climara (estradiol)." Berlex Laboratories
  6. (2001) "Product Information. Estrace (estradiol)." Warner Chilcott Laboratories
  7. (2001) "Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals
  8. (2001) "Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals
  9. "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
  10. (2001) "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical
  11. "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
  12. (2001) "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories
  13. (2001) "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical
  14. (2001) "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories
  15. "Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical
  16. (2001) "Product Information. Emcyt (estramustine)." Pharmacia and Upjohn
  17. (2001) "Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical
  18. "Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical
  19. (2001) "Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn
  20. "Product Information. Estinyl (ethinyl estradiol)." Schering Corporation
  21. (2001) "Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc
  22. (2001) "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories
  23. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical
  24. (2001) "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories
  25. (2021) "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma
View all 25 references
Moderate

Levonorgestrel (applies to Liletta) cardiovascular disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cerebral Vascular Disorder, History - Thrombotic/Thromboembolic Disorder, Thrombotic/Thromboembolic Disorder

The use of levonorgestrel requires careful assessment and caution in conditions of arterial disease, including stroke and myocardial infarction, and also, in patients with increased blood pressure and coagulopathies.

References

  1. (2001) "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn
  2. (2001) "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn
  3. (2001) "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories
  4. (2001) "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories
  5. (2016) "Product Information. Liletta (levonorgestrel)." Actavis Pharma, Inc.
View all 5 references
Moderate

Progestogens (applies to Liletta) hyperlipidemia

Moderate Potential Hazard, Moderate plausibility.

Some progestogenic agents may elevate plasma LDL levels and/or lower HDL levels, although data have been inconsistent. Patients with preexisting hyperlipidemia may require closer monitoring during progestogen therapy, and adjustments made accordingly in their lipid-lowering regimen.

References

  1. Barnes RB, Roy S, Lobo RA (1985) "Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women." Obstet Gynecol, 66, p. 216-9
  2. Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE (1989) "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception, 39, p. 619-32
  3. Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D (1986) "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet, 24, p. 291-6
  4. Teichmann AT, Wander HE, Cremer P, et al. (1987) "Medroxyprogesterone acetate and lipid metabolic changes." Arzneimittelforschung, 37, p. 573-77
  5. Who Task Force on Long-acting Agents for Fertility Regulation (1986) "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ, 64, p. 587-94
  6. Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV (1993) "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med, 38, p. 207-14
  7. (2001) "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn
  8. (2001) "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn
  9. "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
  10. (2001) "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical
  11. "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
  12. (2001) "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories
  13. (2001) "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical
  14. (2001) "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories
  15. (2001) "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories
  16. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical
  17. (2001) "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories
View all 17 references
Minor

Progestogens (applies to Liletta) weight gain

Minor Potential Hazard, Moderate plausibility. Applicable conditions: Obesity

Progestogens can cause weight gain, which may be significant (as is the case with parenteral medroxyprogesterone) and undesirable in obese patients attempting to lose weight.

References

  1. Leiman G (1972) "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure." Am J Obstet Gynecol, 114, p. 97-102
  2. Amatayakul K, Sivasomboon B, Thanangkul O (1980) "A study of the mechanism of weight gain in medroxyprogesterone acetate users." Contraception, 22, p. 605-22
  3. (2001) "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn
  4. (2001) "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn
  5. "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
  6. (2001) "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical
  7. "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
  8. (2001) "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories
  9. (2001) "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical
  10. (2001) "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories
  11. (2001) "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories
  12. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical
  13. (2001) "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories
View all 13 references

Liletta drug interactions

There are 245 drug interactions with Liletta (levonorgestrel).

Liletta alcohol/food interactions

There are 5 alcohol/food interactions with Liletta (levonorgestrel).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.